BFEC
INSY

Benjamin F. Edwards & Company’s Insys Therapeutics, Inc. INSY Stock Holding History

Benjamin F. Edwards & Company’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-340
Closed -$3K – 1720
2017
Q4 		$3K Buy
340
+190
+127% +$1.24K ﹤0.01% 1460
2017
Q3 		$1K Buy
+150
New +$1.55K ﹤0.01% 1525

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Benjamin F. Edwards & Company's INSY Position: Q1 2018 in Review

Benjamin F. Edwards & Company sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 340 shares — an estimated $3K sold.

Benjamin F. Edwards & Company first reported a position in INSY in Q3 2017 and held it in 2 quarters. The position peaked at $3K in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Benjamin F. Edwards & Company reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 340 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $3K.
  • Benjamin F. Edwards & Company first reported a position in Insys Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Insys Therapeutics, Inc. position peaked at $3K in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2018, filed 17 Apr 2018.